Sun.Dec 17, 2023

article thumbnail

STAT+: Illumina says it will divest Grail, starting a closing chapter for a disastrous deal

STAT

Illumina, the leading maker of DNA sequencing machines, said Sunday that it would divest Grail, the developer of a multi-cancer screening test, which it bought over the objections of regulators in the U.S. and Europe in August 2021. Illumina said the decision to spin Grail off followed a Friday decision of the U.S. Fifth Circuit Court of Appeals, which held that the merger was anti-competitive.

137
137
article thumbnail

‘Gamechanging’ drug to prevent hot flushes wins approval in UK

The Guardian - Pharmaceutical Industry

Veoza, also known as fezolinetant, is prescription-only and will be available privately from January A “gamechanging” drug that prevents hot flushes and could benefit hundreds of thousands of women has been approved for use in the UK. The green light for Veoza, also known as fezolinetant, comes after the US regulator, the Food and Drug Administration, authorised it for use in America in May.

111
111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: The biggest health care deals of 2023

STAT

Every year, the health care industry behaves more and more like a balloon: Squeeze one side, and the other expands. Companies that were once just insurers or just pharmacies are tacking on new business lines. The idea is that when profit inevitably gets squeezed in one, it’ll expand in another. That trend of vertical integration was on full display in 2023, a year when the country’s biggest pharmacy chain bought a primary care provider, and the biggest private insurer branched furt

Insurance 133
article thumbnail

BMS’ LAG-3 RELATIVITY theory fails futility test

pharmaphorum

Bristol-Myers Squibb has abandoned a bid to extend the indications of its combination of PD-1 inhibitor Opdivo and LAG-3 inhibitor relatlimab into colorectal cancer after it failed the phase 3 RELATIVITY-123 trial.

110
110
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

UK firms exploit ADHD medication shortage to push unproven ‘smart’ supplements

The Guardian - Pharmaceutical Industry

Health bosses condemn ‘irresponsible’ targeting of people desperate for NHS help Wellness firms are exploiting a national shortage of ADHD medication to push so-called “smart supplements” as an alternative to prescribed drugs. As patients struggle to get hold of medication – or face years-long waits for NHS assessments – companies are peddling unproved products as a “natural” treatment for attention deficit hyperactivity disorder.

106
106
article thumbnail

Semaglutide Overdose – What Does It Look Like and Why Is It Happening?

Med Ed 101

Semaglutide products have been popping up in news headlines recently, and not because of their continued popularity as effective weight loss medications. Data from poison control centers across the country indicates a drastic increase over the past year in calls related to semaglutide overdose — an increase of over 1500% since 2019 according to a […] The post Semaglutide Overdose – What Does It Look Like and Why Is It Happening?

105
105